Madrigal Pharmaceuticals ... (MDGL)

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock?

Madrigal Pharmaceuticals, Inc.'s Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity, but GLP-1 competition from Novo and Lilly poses significant future challenges. Madrigal's P...

MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.

On Wednesday, Madrigal Pharmaceuticals, Inc. MDGL reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra (resmetirom).

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales up 66% to $103.3m. Despite a net loss of $466m in 2024, Madrigal's cash posi...

Shares of Madrigal Pharmaceuticals (MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday.

Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2024 Earnings Call Transcript

Madrigal (MDGL) came out with a quarterly loss of $2.71 per share versus the Zacks Consensus Estimate of a loss of $4.12. This compares to loss of $5.68 per share a year ago.

MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with tur...

Madrigal Pharma's REZDIFFRA achieved $100-$103M in Q4 sales, marking 61% growth, with market penetration of only 4% relative to TAM, indicating blockbuster potential. Potential competition from GLP-1 ...